Chemomab Therapeutics Ltd. Earnings Per Share Disclosure
Note 13 - Net Loss Per Share Attributable to Ordinary Shareholders
Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued and if the additional ordinary shares of were dilutive. Diluted net loss per share is the same as basic net loss per share of ordinary share, as the effect of potentially dilutive securities is antidilutive.
The following table sets forth the computation of basic and diluted net loss per share attributable to ordinary shareholders for the periods presented:
|
Year ended |
Year ended |
|||||||
|
December 31 |
December 31 |
|||||||
|
2022 |
2021 |
|||||||
|
In USD thousands, except share and per share data |
||||||||
|
Numerator: |
||||||||
|
Net loss |
27,646 |
12,478 |
||||||
|
|
||||||||
|
Denominator: |
||||||||
|
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted |
227,589,288 |
207,468,650 |
||||||
|
|
||||||||
|
Net loss per share attributable to ordinary shareholders, basic and diluted |
0.121 |
0.060 |
||||||
The potential number of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented since including them would have been anti-dilutive are as follows:
|
Year ended |
Year ended |
|||||||
|
December 31 |
December 31 |
|||||||
|
2022 |
2021 |
|||||||
|
Number of shares |
||||||||
|
Outstanding options to purchase ordinary shares |
35,191,540 |
27,003,260 |
||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2022 | Mar 20, 2023 | Showing above |
| 2021 | Mar 30, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.